Authors

Malcolm Ross, MD

Latest:

Dr. Ross on the Unmet Needs in Uterine Carcinosarcoma

Malcolm Ross, MD, University of Pittsburgh, discusses unmet needs for patients with uterine carcinosarcoma.

Malcom Mason, MD

Latest:

Dr. Mason on the Significant Results from the PROTECT Study in Prostate Cancer

Malcom Mason, MD, Cancer Research Wales Professor of Clinical Oncology at Cardiff University, discusses the significant results of the PROTECT study for patients with prostate cancer.

Malini Harigopal, MD

Latest:

Dr. Harigopal on Advances With Breast Cancer Pathology

Malini Harigopal, MD, associate professor of Pathology, interim director of Breast Pathology, Yale School of Medicine, Yale Cancer Center, discusses the advancements in the pathology of breast cancer.

Manali Bhave, MD

Latest:

Sequencing Antibody-Drug Conjugates (ADCs) in HR+/HER2-Low Metastatic Breast Cancer

Laura Spring, MD, and Manali Bhave, MD, discuss sequencing approved antibody-drug conjugates, T-DM1 and sacituzumab govitecan, for hormone receptor-positive, HER2-low metastatic breast cancer after progression on chemotherapy.

Manfred Welslau, MD

Latest:

Dr. Welslau on the Rationale for the REFLECT Trial With Rituximab Biosimilar

Manfred Welslau, MD, discusses the rationale of the prospective REFLECT trial with the rituximab biosimilar SDZ-RTX in patients with diffuse large B-cell lymphoma.

Manish A. Shah, MD

Latest:

Dr Shah on 5-Year Outcomes With Pembrolizumab/Chemo in Esophageal Cancer

Manish A. Shah, MD, discusses 5-year outcomes from the KEYNOTE-590 trial of frontline pembrolizumab plus chemotherapy in patients with esophageal cancer.

Manish A Shah, MD, Weill Cornell Medicine

Manish A. Shah, MD, Weill Cornell Medicine, New York-Presbyterian Hospital

Manish Kohli, MD

Latest:

Dr. Kohli on the Use of Enzalutamide and Apalutamide in mHSPC

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Manish R. Patel, DO

Latest:

Dr. Patel on Key Updates from First-Line Trials in NSCLC

Manish Patel, DO, discusses updates in treatment with a PD1 and CTLA-4 inhibitor in non–small cell lung cancer.

Manish R. Sharma, MD, University of Chicago

Manish Shah, MD, Weill Cornell Medical College

Manish Shah, MD, Weill Cornell Medicine

Manish Shah, MD

Latest:

Dr Shah on Responses With Pembrolizumab Plus Chemo By PD-1 Status in Esophageal Cancer

Manish A. Shah, MD, discusses how pembrolizumab with chemotherapy impacts immune responses in advanced esophageal cancer according to PD-L1 status.

Manju P. Paul, MD

Latest:

Dr. Paul Discusses the Pulmonologist's Role in Managing Patients With Lung Cancer

Manju P. Paul, MD, assistant professor of medicine at Upstate University Hospital, discusses the pulmonologist’s role as part of the multidisciplinary approach in treating patients with non–small cell lung cancer (NSCLC).

Manmeet Ahluwalia, MD, FACP

Latest:

Novel Agents Show Signs of Efficacy Against Brain Metastases

Although many new therapies have been introduced in a range of cancer types, brain metastases remain a serious neurological complication in patients with advanced malignancies.

Manoj K. Jain, MD

Latest:

Dr. Jain on the Use of Diagnostic Tracers in Prostate Cancer

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Mansoor Raza Mirza, MD

Mansoor R. Mirza, MD is medical & radiation oncologist, involved in the management of gynaecologic cancers. He is Chief Oncologist at Rigshospitalet, Copenhagen and Medical Director of Nordic Society of Gynaecological Oncology

Latest:

Dr Mirza on Long-Term Response Data for Dostarlimab Plus Chemo in Advanced Endometrial Cancer

Manuel Hidalgo, MD, PhD

Latest:

Dr. Hidalgo Discusses the Phase III TRYbeCA1 Trial in Pancreatic Cancer

Manuel Hidalgo, MD, PhD, professor of medicine, Harvard Medical School, chief, Department of Hematology/Oncology, Beth Israel Deaconess Medical Center, discusses the phase III TRYbeCA1 trial in patients with advanced pancreatic adenocarcinoma.

Manuel Hidalgo, MD, PhD, Harvard Medical School and Beth Israel Deaconess Medical Center